Business context and reporting period
Cardiol Therapeutics Inc. filed this Form 20-F annual report for the fiscal year ended December 31, 2023. The company is a clinical-stage life sciences business developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx (pharmaceutically manufactured cannabidiol), is in Phase II trials for recurrent pericarditis and acute myocarditis; its subcutaneous candidate, CRD-38, remains in preclinical development for heart failure. The audited financial statements are prepared under IFRS and presented in Canadian dollars (C$).
Financial performance and position
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | C$0 | C$0 |
| General and administrative expense | C$15.56 million | C$22.37 million |
| Research and development expense | C$14.22 million | C$18.96 million |
| Net loss | C$28.13 million | C$30.93 million |
| Basic and diluted loss per share | C$0.44 | C$0.49 |
| Cash used in operating activities | C$25.18 million | C$27.22 million |
| Cash and cash equivalents at year-end | C$34.93 million | C$59.47 million |
| Total assets | C$36.70 million | C$62.03 million |
| Total liabilities | C$8.45 million | C$9.83 million |
The company reported no product revenue in 2023 or 2022; operating margins are therefore not meaningful. FY 2023 interest income was C$2.04 million. There was no variable- or fixed-interest-bearing debt reported; liabilities included accounts payable and accrued liabilities, lease liabilities, and a derivative liability. Current assets of C$36.15 million exceeded current liabilities of C$8.30 million, implying working capital of approximately C$27.86 million.
Material changes versus the prior year
- Net loss narrowed by about 9% from FY 2022. General and administrative expense declined about 30%, and research and development expense declined about 25%.
- Operating cash outflow improved by about 8%, but year-end cash fell by C$24.54 million, or about 41%, reflecting ongoing operating use of funds.
- Interest income increased to C$2.04 million from C$1.24 million. The gain from remeasurement of the derivative liability fell to C$0.18 million from C$6.24 million, partially offsetting the lower operating loss.
- No equity was issued under the C$50 million 2022 at-the-market program; it expired after year-end without any shares sold. Outstanding common shares were 65,352,279 at December 31, 2023.
Outlook, management commentary, and key risks
- Clinical programs: In January 2024, ARCHER had passed 50% enrollment; management anticipated completing recruitment in Q3 2024 and budgeted approximately C$6 million in additional trial costs. MAvERIC-Pilot completed enrollment in February 2024; management expected topline results in Q2 2024 and extension data in the second half of 2024, with approximately C$1 million budgeted to complete the study. These are forward-looking expectations, not reported outcomes.
- CRD-38: The company reported positive 2023 pharmacokinetic testing and was scaling up manufacturing to support toxicity studies. Timing and total development costs remain undetermined.
- Funding and going concern: The company has a history of losses, negative operating cash flow, no commercialized products, and expects further financing may be needed. Management concluded that working capital supported planned expenditure levels and that a material going-concern uncertainty did not exist at the reporting date. Future financing terms and availability are uncertain and may dilute shareholders.
- Development and regulatory risks: Clinical outcomes, trial timing, regulatory approval, commercialization, reimbursement, and manufacturing supply are uncertain. The company discontinued its LANCER COVID-19 trial in 2022 because eligible-patient recruitment and event rates were lower than anticipated.
- Other investor considerations: Cardiol stated it believed it was a passive foreign investment company (PFIC) for U.S. tax purposes in 2023 and expected it might remain one in 2024. A 10% change in the U.S.-dollar exchange rate versus the Canadian dollar was estimated to affect reported loss by approximately C$2.77 million. No dividends are anticipated in the foreseeable future.
- Governance and compliance: Management reported that disclosure controls and internal control over financial reporting were effective at year-end and that a previously identified material weakness involving certain consultant share-based compensation had been remediated. The auditor did not provide an ICFR attestation because the company qualifies as an emerging growth company. The financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Whether ARCHER and MAvERIC-Pilot results, enrollment timelines, and projected remaining costs match subsequent disclosures.
- Cash runway and financing needs against actual operating cash use, trial spending, and any new funding or partnership arrangements.
- Potential dilution from outstanding warrants, options, RSUs, and PSUs, including awards redeemed after year-end.
- The company’s annual PFIC status and related U.S. tax reporting implications, in consultation with a tax adviser.
- Related-party research and development spending: C$1.23 million was recognized in 2023 for a company related to director Peter Pekos; C$416,792 remained payable at year-end.
- Post-year-end share-count changes and Nasdaq listing compliance. The company reported regaining minimum-bid-price compliance in January 2024.